Different prognoses for these two subgroups have been demonstrated, regardless of the IPI risk.6,8,11,15 More recently, Hans et al. have demonstrated similar results using immunohistochemical profiling, for other markers such as CD10, Bcl-6 and IRF4 (MUM1).11 Contrary to these studies, which evaluated patients with mixed IPI risk, we evaluated cases restricted to high-risk DLBCL that did not show survival differences between the GCB-like and ABC-like subgroups. This evidence concerns the gene IRF4 and diffuse large B-cell lymphoma.